La chaîne d'options affiche les données clés des options sur actions de Lion Group Holding à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Lion Group Holding..

Lion Group Holding (NASDAQ:LGHL) Stock, Chaîne d'Options

Lion Group Holding

Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.

Lion Group Holding Ltd. - American Depositary Share

Lion Group Holding Ltd

Lion Group Holding Ltd Warrants (17/06/2025)

Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) has outperformed the market over the past 15 years by 6.35% on an annualized basis producing an average annual return of 18.41%. Currently, Arthur J. Gallagher has a market capitalization of $81.10 billion. 
Buying $100 In AJG: If an investor had bought $100 of AJG stock 15 years ago, it would be worth $1,236.29 today based on a price of $317.13 for AJG at the time of writing.
<h3>Arthur J. Gallagher's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750449614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In Arthur J. Gallagher 15 Years Ago Would Be Worth This Much Today

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.
In connection with the offering, the Company will issue 1,180,877 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase price of $3.60 per share, priced at-the-market under Nasdaq rules.
The offering is expected to close on or about June 23, 2025, subject to the satisfaction of customary closing conditions.

Biotech

Offerings

General

SHPH

Shuttle Pharmaceuticals Announces Pricing Of $4.25M Private Placement At A Purchase Price Of $3.60 Per Share

Major cryptocurrencies are seeing red as markets cooled off from recent gains. 
Despite ongoing institutional accumulation, prices dipped following a technical rejection that triggered a wave of <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46027460/bitcoin-veteran-trader-goes-long-again-after-15-million-in-losses-will-third-time-be-the-ch">short-term caution</a>. As geopolitical tensions rise, market sentiment appears risk-off heading into the weekend.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$103,120.56</td>
<td>-1.2%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,408.11</td>
<td>-4.1%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$138.63</td>
<td>-4.8%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.11</td>
<td>-2.5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1617</td>
<td>-5%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001127</td>
<td>-2.6%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume decreasing by 27.8% and daily active addresses falling by 2.5%. Transactions greater than $100,000 are down from 10,533 to 9,611 in a single day. Exchanges netflows are down by 741.9%.</li>
<li>Coinglass data reports 130,673 traders were liquidated in the past 24 hours, with the total liquidations at $467.69 million.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46025230/why-a-public-healthcare-firm-wants-to-hold-more-bitcoin-than-most-countries">Why A Public Healthcare Firm Wants To Hold More Bitcoin Than Most Countries</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46019280/trump-connected-company-pulls-back-from-family-crypto-business">Trump-Connected Company Pulls Back From Family Crypto Business</a></li>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46024346/xrp-next-big-etf-bet-polymarket-bettors-predict">Why XRP Could Be The Next Big ETF Bet And What Polymarket Traders Know That You Don&#8217;t</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46025145/saks-stablecoin-bill-treasury-buying-trump-ties-cloud-push">Sacks Says New Bill Allows Stablecoins To Soak Up Trillions—But Trump Ties Cloud The Push</a></li>
<li><a href="https://www.benzinga.com/crypto/25/06/46021402/peter-schiff-says-he-intends-to-launch-gold-backed-stablecoins-deems-dollar-as-a-flawed-fiat-currency">Peter Schiff Says He Intends To Launch Gold-Backed Stablecoins, Deems Dollar As A &#8216;Flawed&#8217; Fiat Currency</a></li>
<li><a href="https://www.benzinga.com/news/social-media/25/06/46033842/did-tiktok-try-to-bribe-trump-with-300m-in-crypto-the-company-fires-back">Did TikTok Try to Bribe Trump With $300M In Crypto? The Company Fires Back</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46034000/circles-flagship-stablecoin-usdc-set-for-rapid-growth-analyst-says-regulatory-climate-key">Circle&#8217;s Flagship Stablecoin USDC Set For Rapid Growth, Analyst Says Regulatory Climate Key</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>SPX6900 (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SPX</a>)</td>
<td>$1.11</td>
<td>-16.8%</td>
</tr>
<tr>
<td>AB (CRYPTO: AB)</td>
<td>$0.01260</td>
<td>-12.7%</td>
</tr>
<tr>
<td>Sonic (CRYPTO: S)</td>
<td>$0.2816</td>
<td>-12.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: CrediBULL Crypto <a href="https://x.com/CredibleCrypto/status/1936116976390152258">believes</a> Bitcoin may have bottomed at range lows, potentially forming a triple tap base. He's opened a long position, his first in weeks, expecting a bounce from the current green support zone. If this level breaks, the downside target is $94,000–$98,000, though he views both outcomes as technically healthy corrections.
Rekt Capital <a href="https://x.com/rektcapital/status/1936124289360523713">highlights</a> Bitcoin's continued defence of the $104,400 level, now holding for six straight weeks. All eyes are on the weekly close; a seventh consecutive hold would confirm this zone as a solid accumulation base and strengthen the case for near-term upside.
Michael van de Poppe notes that Bitcoin faced rejection at a key resistance, triggering a broader market correction. A liquidity sweep may be underway, creating the conditions for potential buy-the-dip setups. He advises patience and careful monitoring of support levels.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Crucial level for <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> did reject and we see the correction. I suppose we&#39;ll see more downside and a liquidity sweep taking place in the markets. Buy the dip opportunities. <a href="https://t.co/Lnb6yh9ujp">pic.twitter.com/Lnb6yh9ujp</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1936100732731900393?ref_src=twsrc%5Etfw">June 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
ShardiB2 warns that Bitcoin, like the rest of the market, failed to hold important support levels, signaling fading momentum. With risk-off sentiment heading into the weekend, traders are cautious and reluctant to maintain long positions.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Failed like the entire market&#8230; no one wants to be long into the weekend&#8230; <a href="https://t.co/H8ci36nOx5">pic.twitter.com/H8ci36nOx5</a>
&mdash; Don&#39;t follow Shardi B if you hate Money (@ShardiB2) <a href="https://twitter.com/ShardiB2/status/1936073074723426772?ref_src=twsrc%5Etfw">June 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
 • <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46036394/bitcoin-quietly-entered-a-new-era-in-march-heres-whats-really-behind-it">Bitcoin Quietly Entered A New Era In March: Here&#8217;s What&#8217;s Really Behind It</a>
Photo: Chinnapong via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$DOGE

$ETH

$SHIB

$SOL

$SPX

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Pull Back After Technical Rejection — 'No One Wants To Be Long Into The Weekend'

WIIM

MDLZ

Mondelez International shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $68 to $78.

Shares of Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) shares are trading lower by 2.23% to $169.01 Friday afternoon, as the semiconductor sector broadly declined following <a href="https://www.benzinga.com/markets/tech/25/06/46035836/nvidia-broadcom-marvell-and-other-chip-stocks-fall-on-unexpected-us-move">reports</a> that the U.S. plans to end export waivers allowing chipmakers to ship American technology to China.
What To Know: The move, reported by The Wall Street Journal, is expected to tighten restrictions on companies such as Taiwan Semiconductor, Samsung Electronics and SK Hynix, which have relied on <a href="https://www.benzinga.com/markets/tech/25/06/46035836/nvidia-broadcom-marvell-and-other-chip-stocks-fall-on-unexpected-us-move">exemptions</a> to use U.S. equipment in their Chinese operations.
Applied Materials, a leading supplier of semiconductor manufacturing equipment, stands to be directly affected. The company provides the tools and materials essential for fabricating chips, including deposition, etching and inspection systems.
Read Also: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46030895/the-palantir-effect-momentum-stocks-are-making-a-killing-like-never-before">The Palantir Effect: Momentum Stocks Are Making A Killing Like Never Before</a>
AMAT's revenue is closely tied to global chip production, especially in China, the world&#8217;s largest semiconductor market. If key customers face new licensing barriers or halt equipment purchases due to regulatory uncertainty, AMAT's sales could suffer.
The policy shift reflects an ongoing U.S. effort to curb Chinese access to advanced chip technologies amid national security concerns. Industry leaders like Arm Holdings CEO Rene Haas and Nvidia's Jensen Huang have criticized the approach, warning it could slow global innovation and disrupt supply chains. 
Investors appear to be pricing in the risk of reduced demand from Chinese chipmakers, leading to Friday's selloff.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMAT has a 52-week high of $255.89 and a 52-week low of $123.74.
<h2 class="wp-block-heading">How To Buy AMAT Stock</h2>
By now you're likely curious about how to participate in the market for Applied Materials&#8217; &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Applied Materials&#8217;, which is trading at $169.89 as of publishing time, $100 would buy you 0.59 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/eurozone/25/06/46026714/this-rare-market-dynamic-preceded-the-dot-com-crash-its-back-in-2025">This Rare Market Dynamic Preceded The Dot-Com Crash — It&#8217;s Back In 2025</a></li>
</ul>
Image: Shutterstock

AMAT

What Applied Materials (AMAT) Stock Is Falling

Politics

Global

Trump Says Giving Iran A Period Of Time, Two Weeks Would Be Maximum

Movers

System1 Shares Resume Trade After Circuit Breaker Halt

A surge in demand for weight-loss and diabetes medications, paired with fears of incoming tariffs, has propelled Ireland to the center of a pharmaceutical trade boom with the U.S., dramatically widening the <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">bilateral trade imbalance</a>.
This year alone, $36 billion worth of hormone ingredients—essential for popular drugs like GLP-1 treatments and insulin analogs—have been flown from Ireland to the U.S., more than doubling last year&#8217;s total.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/health/pharma/how-weight-loss-drugs-blew-out-the-u-s-trade-deficit-2d8c668c" rel="noreferrer noopener">stated</a> that these pharmaceutical ingredients weighed 23,400 pounds, were highly concentrated, and shipped in temperature-controlled containers.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45998123/scholar-rocks-atrophy-drug-when-combined-with-eli-lillys-zepbound-shows-around-55-better-muscle-preservation-in-weight-loss-study" rel="noreferrer noopener">Scholar Rock&#8217;s Atrophy Drug When Combined With Eli Lilly&#8217;s Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study</a>
Nearly all were bound for Indiana, where Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), the maker of blockbuster drugs Zepbound and Mounjaro, is based.
The company began manufacturing these products in its Kinsale, Ireland facility last year and is now preparing to seek U.S. approval for a weight-<a target="_blank" href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" rel="noreferrer noopener">loss pill, orforglipron</a>.
This airlift of peptide and protein-based hormones, compounds that regulate appetite and metabolism, has played a key role in pushing Ireland to the second spot on U.S. goods-trade deficits, trailing only China.
In the first four months of 2025, the U.S. imported $71 billion in goods from Ireland, with hormone ingredients accounting for nearly half.
The rush stems from both commercial and geopolitical pressures. Former President Donald Trump&#8217;s shifting trade policies have triggered stockpiling by pharmaceutical companies racing to beat tariff deadlines.
A Section 232 investigation launched in April could lead to new levies on imported <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44847222/trump-administration-opens-probe-into-foreign-drug-imports-eyes-tariffs-under-national-security-law" rel="noreferrer noopener">drugs and active ingredients</a>.
The report added that Ireland, home to just 5.4 million people, is a hub for U.S. pharmaceutical manufacturing, partly due to its favorable tax structure.
Giants like AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) produce leading treatments such as Botox and Keytruda there.
Ireland&#8217;s central bank <a target="_blank" href="https://www.benzinga.com/markets/eurozone/25/06/46034817/us-multinationals-including-pharma-firms-power-over-5-of-eurozone-economy-ecb-says" rel="noreferrer noopener">attributed</a> a nearly 10% GDP growth in Q1 to soaring pharma exports.
However, the trade imbalance has drawn scrutiny. Ireland was recently added to the U.S. Treasury Department&#8217;s currency manipulation watchlist. Dan O&#8217;Brien of Dublin&#8217;s Institute of International and European Affairs said the attention is &#8220;definitely not welcome,&#8221; especially as Ireland alone accounts for a large share of the U.S.-EU deficit.
The logistical strain is also evident. Pharma shipments from Ireland to the U.S. more than doubled in March and April, with logistics firms working overtime. Lufthansa Cargo and Kuehne + Nagel reported increased volumes, although activity began to slow in April as U.S. warehouses filled up.
As the White House pushes to onshore drug manufacturing, companies like Lilly and Merck are ramping up domestic investments, aiming to reduce reliance on foreign supply chains amid regulatory uncertainty.
Price Action: LLY stock is down 2.55% at $765.05&nbsp;at the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst</a></li>
</ul>
Photo by M7kk via Shutterstock

Large Cap

Health Care

Media

ABBV

Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere

Shares of Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) are trading flat on Friday afternoon but are higher by 6% for the week, despite no new company-specific developments. The gains come as investors remain upbeat on AI infrastructure names following last week's announcement of a strategic collaboration between SMCI and Ericsson.
What To Know: The two firms signed a Memorandum of Understanding to combine Ericsson's 5G wireless capabilities with Super Micro's edge AI platforms. The <a href="https://www.benzinga.com/markets/tech/25/06/45854883/ericsson-supermicro-partner-to-bring-5g-powered-ai-to-factories-retail-and-hospitals">bundled offering</a> aims to simplify and accelerate Edge AI deployment across industries including healthcare, retail and manufacturing.
Super Micro has also been expanding its presence in the AI server market. Last week, the company <a href="https://www.benzinga.com/markets/tech/25/06/45881923/supermicro-teams-up-with-nvidia-to-supercharge-europes-ai-factories-with-powerful-server-solutions">unveiled</a> over 30 new solution stacks in Europe for Nvidia's Blackwell architecture, including deployments for HGX B200 and GB200 NVL72.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46030175/sofi-stock-rises-this-week-amid-bullish-guidance-whats-going-on">SoFi Stock Rises This Week Amid Bullish Guidance: What&#8217;s Going On?</a>
These systems are designed to deliver rapid AI deployment at scale and include advanced cooling technologies to meet increasing compute demands.
Despite this week's positive momentum, Super Micro Computer stock remains down more than 50% over the past year. In its latest earnings, the company <a href="https://www.benzinga.com/news/earnings/25/05/45236823/super-micro-computer-stock-slips-after-q3-results-uncertainty-and-tariffs-may-have-a-short-term-impact-ceo-says">missed revenue</a> and margin estimates, citing delays tied to next-gen AI platform transitions and inventory pressures.
Still, analysts remain optimistic, with Raymond James recently initiating coverage, highlighting Super Micro's strong positioning in the AI server space.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SMCI has a 52-week high of $101.40 and a 52-week low of $17.25.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46029775/whats-going-on-with-amd-stock-15">What&#8217;s Going On With AMD Stock?</a>
<h2 class="wp-block-heading">How To Buy SMCI Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Super Micro Computer&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

SMCI

What's Going On With Super Micro Computer (SMCI) Stock?

Elon Musk&#8217;s ambitious artificial intelligence venture, xAI, is reportedly rapidly exhausting its financial reserves, with estimates suggesting a staggering monthly expenditure of approximately $1 billion, according to a <a href="https://www.bloomberg.com/news/articles/2025-06-17/musk-s-xai-burning-through-1-billion-a-month-as-costs-pile-up" target="_blank" rel="noreferrer noopener">recent report</a> by Bloomberg. 
While the claim has been <a href="https://twitter.com/elonmusk/status/1935232017626710285?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1935232017626710285%7Ctwgr%5Ee39bc6c07e16fa991f8dc80e011de751ed04d645%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fwww.teslarati.com%2Felon-musk-slams-bloomberg-xai-cash-burn-claims%2F">rebuked by Musk in an X post</a>, the estimate isn&#8217;t inconceivable. One X commentor <a href="https://x.com/CosmicNomad44/status/1935037603838861723" target="_blank" rel="noreferrer noopener">noted</a>, &#8220;If you got that number from the fact they raised $6 billion six months ago and have already spend it, they could've spend most of it in one go on GPUs.&#8221; This underscores the extraordinary capital demands of developing sophisticated AI systems in today&#8217;s fiercely competitive landscape, raising crucial questions for investors regarding the long-term viability of AI startups operating outside the umbrella of tech giants with deep pockets.
<h2 class="wp-block-heading">The Reportedly Billion-Dollar Monthly Burn</h2>
Founded in 2023, xAI emerged as Musk&#8217;s response to the perceived ideological bias in existing AI systems. The company&#8217;s flagship product, Grok, was designed to compete with OpenAI&#8217;s ChatGPT and Google&#8217;s Bard (now Gemini), but the pursuit of cutting-edge AI technology comes with a hefty price tag. 
This reportedly $1 billion monthly expenditure likely stems from the substantial computing infrastructure required to train large language models (LLMs). The Economic Times report indicates that xAI&#8217;s costs are predominantly directed toward purchasing and operating the necessary hardware – specifically NVIDIA&#8217;s advanced GPUs that have become the industry standard for AI training.
The enormity of this endeavor is further compounded by the <a href="https://www.benzinga.com/markets/commodities/25/06/45728009/tomorrows-energy-crisis-mits-alarming-analysis-of-ai-power-consumption" target="_blank" rel="noreferrer noopener">substantial energy requirements</a> and corresponding costs.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003431/Depositphotos_784722484_XL-1024x683.jpg" alt="" class="wp-image-14606" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003431/Depositphotos_784722484_XL-1024x683.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003431/Depositphotos_784722484_XL-300x200.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003431/Depositphotos_784722484_XL-768x512.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003431/Depositphotos_784722484_XL.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Source: DepositPhotos License</figcaption></figure>
<h2 class="wp-block-heading">Funding Challenges and Valuation Questions</h2>
Despite securing $6 billion in a funding round earlier this year, which valued the company at $24 billion, xAI&#8217;s current burn rate (if reports can be believed), implies that this capital could be depleted in as little as six months without additional investment, presenting a harsh reality check for investors who have been pouring money into AI startups at increasingly lofty valuations. This situation is not unique to xAI, as the AI sector as a whole is characterized by astronomical valuations coupled with equally substantial operating costs. 
For instance, OpenAI reportedly operates with a monthly burn rate of approximately $700 million, although it has reported over <a href="https://www.cnbc.com/2025/06/09/openai-hits-10-billion-in-annualized-revenue-fueled-by-chatgpt-growth.html">$10 billion in annual revenue</a> and is valued at over $80 billion.
Anthropic, another major player in the AI landscape, has secured significant backing from Amazon and Google, highlighting the capital-intensive nature of this industry. As Sarah Johnson, AI investment analyst at Morgan Stanley, observed in a recent research note, &#8220;We&#8217;re witnessing a capital-intensive race that favors organizations with either massive funding rounds or the backing of tech giants with effectively unlimited resources.&#8221; This raises significant challenges for independent players, which must navigate the complexities of sustaining operations without continuous capital infusion.
<h2 class="wp-block-heading">Strategic Implications for AI Investors</h2>
For investors in the AI sector, xAI&#8217;s financial situation per reports, offers several important insights. Firstly, the enormous infrastructure costs associated with AI development create significant barriers to entry, potentially limiting the field to well-funded startups and established tech companies. This, in turn, suggests that infrastructure providers like NVIDIA may represent more stable investment opportunities than AI startups themselves. Furthermore, the reportedly high burn rates across the industry imply that consolidation is likely, with smaller players either being acquired or failing to secure the necessary funding to compete.
The scarcity of technical talent in the AI space continues to drive up operational costs, as the limited pool of AI researchers capable of developing cutting-edge models commands premium salaries. Moreover, despite the hype surrounding generative AI, few companies have demonstrated sustainable business models, with xAI&#8217;s Grok chatbot currently available to premium subscribers on X (formerly Twitter) generating insufficient revenue to offset development costs.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003608/Depositphotos_673884330_XL-1024x576.jpg" alt="" class="wp-image-14607" style="width:926px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003608/Depositphotos_673884330_XL-1024x576.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003608/Depositphotos_673884330_XL-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003608/Depositphotos_673884330_XL-768x432.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/19003608/Depositphotos_673884330_XL.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Source: DepositPhotos License</figcaption></figure>
<h2 class="wp-block-heading">Musk&#8217;s Unique Position</h2>
Elon Musk&#8217;s unique position, with his personal wealth and control of multiple companies, creates a distinct dynamic for xAI. Unlike other startups facing similar challenges, xAI has the potential to tap into Musk&#8217;s personal resources or leverage synergies with his other ventures. As tech analyst Ben Thompson noted in his Stratechery newsletter, &#8220;Musk has demonstrated a willingness to personally fund his priorities in the past; the question now is how much he&#8217;s willing to commit to xAI when his attention is divided across multiple companies.&#8221;
<h2 class="wp-block-heading">The Competitive Landscape</h2>
xAI&#8217;s financial predicaments must be contextualized within the broader competitive landscape, where OpenAI continues to reign supreme in the consumer-facing generative AI market with ChatGPT, bolstered by Microsoft&#8217;s substantial investment and computing resources. Meanwhile, Google&#8217;s Gemini models and Anthropic&#8217;s Claude have also garnered significant traction, further intensifying the competition.
To justify its valuation and attract additional investment, xAI must demonstrate a meaningful differentiation from these established players, which has proven to be a daunting task. Although Grok has garnered attention for its less-filtered responses compared to its competitors, it has yet to demonstrate technological superiority that would justify the enormous development costs incurred thus far.
Still, that's not stopping venture capital firms like TPG, Sequoia and others to consider <a href="https://www.nytimes.com/2025/06/12/business/xai-elon-musk-investors.html" target="_blank" rel="noreferrer noopener">investing up to $250 Million in xAI</a>, according to recent reports.
<h2 class="wp-block-heading">Navigating the Uncertain Future: Key Indicators for Investors</h2>
As the AI landscape continues to evolve at a breakneck pace, investors should remain vigilant and monitor several key indicators that will shape xAI&#8217;s financial outlook. These include:
<ul class="wp-block-list">
<li>Funding Announcements: The announcement of additional funding rounds for xAI would be a significant indicator of continued investor confidence, despite the reportedly high burn rate, which has raised concerns among stakeholders.</li>
<li>Technical Benchmarks: Independent evaluations of Grok compared to its competitors will provide valuable insights into whether xAI&#8217;s massive investment is yielding tangible technological advantages, thereby justifying its enormous development costs.</li>
<li>Monetization Strategies: The development of new revenue streams beyond X premium subscriptions would significantly improve the company&#8217;s financial prospects, enabling it to sustain its operations and continue investing in AI research and development.</li>
<li>Regulatory Developments: The increasing regulatory scrutiny of AI could have a disproportionate impact on smaller players, which may lack the resources to navigate the complex compliance requirements, thereby exacerbating their financial challenges.</li>
</ul>
<h2 class="wp-block-heading">Looking Forward</h2>
The AI sector&#8217;s economics continue to evolve rapidly, with the true winners and losers yet to be determined. For investors, xAI&#8217;s financial situation (if reports were to be believed), serves as a cautionary tale about the capital-intensive nature of AI development, while also highlighting the significant challenges that even visionaries like Elon Musk face in this fiercely competitive landscape.

Opinion

Tech

Musk's xAI Reportedly Burns $1 Billion Monthly: Why That Matters To AI Investors

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has filed a federal lawsuit against former engineer Zhongjie "Jay" Li, alleging that he stole trade secrets tied to the company's ambitious <a href="https://www.benzinga.com/markets/equities/25/05/45536080/elon-musk-says-teslas-optimus-can-learn-tasks-by-watching-youtube-videos-just-like-a-human">Optimus</a> humanoid robot program, and used them to launch a competing Silicon Valley startup,<a href="https://www.bloomberg.com/news/articles/2025-06-12/tesla-sues-ex-optimus-engineer-alleging-theft-of-robotic-trade-secrets"> Bloomberg</a> reports.
The lawsuit, filed June 11 in the U.S. District Court for the Northern District of California, claims Li downloaded proprietary data related to Optimus&#8217;s robotic hand systems just before leaving Tesla in September. According to the<a href="https://assets.bwbx.io/documents/users/iqjWHBFdfxIU/rse3WjF_iZ1k/v0"> complaint</a>, the files were stored on two personal smartphones.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Just days after his departure, Li incorporated Proception, a Palo Alto-based robotics startup now marketing humanoid robot hands that Tesla claims in the filing are strikingly similar to its Optimus designs. Tesla alleges the resemblance stems from stolen intellectual property rather than original engineering.
"Defendants took a shortcut: theft," the company said in the lawsuit, accusing Li and Proception of bypassing "the laborious process of development" by leveraging sensitive material from Tesla's multibillion-dollar research effort.
<h2 class="wp-block-heading">Tesla's Optimus Robot and What's at Stake in the Lawsuit</h2>
Optimus is Tesla's long-term bet on integrating <a href="https://www.benzinga.com/news/25/05/45185633/ups-explores-humanoid-robots-as-figure-ai-secures-675m-from-jeff-bezos-openai-and-intel-targeting-9b-revenue-by-2029">humanoid robots</a> into both industrial and personal environments. According to CEO Elon Musk, the robot's hand is one of its most complex and valuable components, featuring highly advanced sensors and mechanical dexterity, Bloomberg says.
During Tesla's earnings call on Jan. 29, Musk<a href="https://www.fool.com/earnings/call-transcripts/2025/01/29/tesla-tsla-q4-2024-earnings-call-transcript/"> said</a>, "Optimus will be overwhelmingly the value of the company," emphasizing the robot's pivotal role in Tesla's future roadmap. The company claims in the lawsuit that its investment in Optimus runs into the billions, and each step of progress requires extensive research, testing, and capital.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
&#8220;Although Tesla does not disclose the precise year-over-year investments in Optimus, the research and development costs are in the billions of dollars. Such an ambitious project demands unparalleled expertise and substantial time and financial commitment to achieve even incremental progress,&#8221; the filing reads.
Tesla's filing includes an internal email from last August warning employees that company devices and accounts were monitored and that any mishandling of data would trigger investigations.
<h2 class="wp-block-heading">Proception's Rapid Rise Now Faces Legal Scrutiny</h2>
Li<a href="https://www.linkedin.com/in/jaylicareer/"> lists</a> himself as the founder and CEO of Proception on LinkedIn, where he describes the company's mission as &#8220;tackling one of the most challenging and exciting humanoid projects of our time.&#8221;
The lawsuit, seeks both compensatory and exemplary damages, along with a permanent injunction barring Proception and its team from using any of Tesla's trade secrets. Tesla has also requested a jury trial.
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Tesla's legal team characterized the alleged behavior as a calculated attempt to exploit corporate investments and engineering breakthroughs for personal commercial gain.
&#8220;Their conduct is not only unlawful trade misappropriation—it also constitutes a calculated effort to exploit Tesla's investments, insights, and intellectual property for their own commercial gain,&#8221; the filing says.
As Tesla expands its footprint beyond electric vehicles into robotics and AI, the outcome of this case may send a clear message about how tech giants will defend innovation in an era of increasing startup competition.
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

TSLA

Tesla Sues Ex-Engineer's Startup Over Alleged Theft Of Billion-Dollar Robot Tech: 'Defendants Took A Shortcut: Theft,' Musk's Company Says

Investor caution dominated Wall Street this week, as escalating tensions between Israel and Iran fueled fears of potential U.S. involvement. Plus, the Federal Reserve's decision to keep rates as is peeved President Donald Trump.
The Federal Reserve kept interest rates steady at 4.25%-4.5% for the fourth consecutive meeting, <a href="https://www.benzinga.com/markets/economic-data/25/06/46004338/no-rate-cuts-yet-fed-flags-slower-growth-sticky-inflation">reaffirming its cautious stance. </a>
Overall economic uncertainty has &#8220;diminished&#8221; since March, but the Fed warns that risks remain elevated. Policymakers maintain their median projection of two rate cuts in 2025, while trimming the 2026 outlook from three cuts to two — signaling a slightly more hawkish stance.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46035360/stock-market-today-news-sp500-nasdaq-trump-iran-bitcoin">S&amp;P 500 Extends Retreat From Highs, Bitcoin Falls Below $103,000: What&#8217;s Driving Markets Friday?</a>
<h3 class="wp-block-heading">Powell Defends The Decision</h3>
Federal <a href="https://www.benzinga.com/news/politics/25/06/45999380/trump-powell-again-markets-breathe-iran-rejects-demands">Reserve Chair Jerome Powell</a> defended the pause. He argues that while inflation has moderated, it is still too high to justify rate reductions. He cited new inflationary pressures stemming from tariffs tied to <a href="https://www.benzinga.com/topic/tariffs">trade policy changes</a>.
The Fed now forecasts 2025 headline inflation at 3%, up from 2.7% in March. Meanwhile, GDP growth was revised downward to 1.4% in 2025, from a prior estimate of 1.7%.
However, in a Friday interview with CNBC, Federal Reserve Governor Christopher Waller said the U.S. central bank could start cutting interest rates <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46035535/fed-guv-says-rate-cuts-july-rate-sensitive-etfs-fed-pivot-looms">as early as July</a>.
Waller is a Trump appointee.
Trump, meanwhile, took to calling Powell names in a social media post, labeling the Fed Chair "an American disgrace," arguing that the Fed&#8217;s inaction costs the U.S. billions in higher interest payments.
Federal Housing Finance Agency Director Bill Pulte echoed the sentiment, calling for Powell's immediate resignation and blaming him for damaging the housing market. <a href="https://www.benzinga.com/markets/25/06/45814493/its-a-buyers-market-redfin-reports-there-are-34-more-sellers-in-the-market-than-buyers" target="_blank" rel="noreferrer noopener">Homes are sitting on the market</a> for weeks or even months while <a href="https://www.benzinga.com/news/25/03/44218740/kevin-oleary-says-prices-arent-going-down-eggs-energy-and-housing-remain-sky-high-but-he-thinks-its-part-of-a-bigger-strategy" target="_blank" rel="noreferrer noopener">prices remain sky high</a> and <a href="https://www.benzinga.com/money/mortgage-rates" target="_blank" rel="noreferrer noopener">mortgage rates</a> remain near 6.8%.
Read Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46006680/powell-holds-line-on-interest-rates-blames-tariff-uncertainty-for-delay-in-cuts">Why Powell Held Rates Steady, And What Trump&#8217;s Iran Comments Could Mean For Markets</a>
<h3 class="wp-block-heading">Energy Sector</h3>
Oil prices, which spiked in the prior week, steadied near $73 per barrel. Powell dismissed parallels with the 1970s oil shocks, stating that while further price spikes are possible, they are unlikely to generate persistent inflationary effects.
Meanwhile, two major Congressional developments shaped market action. The Senate's draft tax bill proposed phasing out clean energy and solar tax credits earlier than anticipated, sparking a steep sell-off in renewables. 
<ul class="wp-block-list">
<li>First Solar Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) tumbled 13% on the week</li>
<li>Enphase Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) dropped 18%, and </li>
<li>Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) plunged 35%.</li>
</ul>
On The Crypto Front: Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) surged 27% on the week after the Senate passed a bill establishing a federal framework for dollar-pegged cryptocurrencies, known as stablecoins.
The bill offers what its supporters argue is <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46025145/saks-stablecoin-bill-treasury-buying-trump-ties-cloud-push">long-awaited regulatory clarity</a> that could unleash capital from institutional investors. Critics, mostly Democrats, say it&#8217;s a conflict of interest <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45995223/genius-stablecoin-bill-clears-senate-but-trumps-crypto-profits-loom-over-momentum">for the Trump family</a>.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/eurozone/25/06/46026714/this-rare-market-dynamic-preceded-the-dot-com-crash-its-back-in-2025">This Rare Market Dynamic Preceded The Dot-Com Crash — It&#8217;s Back In 2025 </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Government

Macro Economic Events

Regulations

Econ #s

Economics

Federal Reserve

COIN

ENPH

FSLR

Wall Street Wavers As Geopolitical Tensions Flare, Trump Renews Attacks On Fed Chair Powell: This Week In Markets

<a href="https://www.bloomberg.com/news/articles/2025-06-20/nyc-settles-on-smaller-driver-pay-bump-after-uber-lyft-pushback?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-20/nyc-settles-on-smaller-driver-pay-bump-after-uber-lyft-pushback?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-20/nyc-settles-on-smaller-driver-pay-bump-after-uber-lyft-pushback?srnd=homepage-americas</a>

Legal

LYFT

UBER

NYC Settles On New Minimum Pay Rules For Rideshare Drivers

LIPO

Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent transformation has led many to ask, &#8220;What exactly changed?&#8221; It is no longer just a speculative asset but a strategic macroeconomic instrument shaped by centralized institutions, sovereign wealth strategies, and <a href="https://www.benzinga.com/topic/bitcoin">long-term financial infrastructure.</a>
What Happened: American cryptocurrency exchange Gemini in an X <a href="https://x.com/Gemini/status/1936061491951587818">post </a>on Friday noted Bitcoin's pivotal shift occurred in March, when the United States officially launched its Strategic Bitcoin Reserve (SBR), elevating the crypto king to a sovereign-grade macro asset, on par with gold and oil.
This move marked the beginning of Bitcoin's institutional era, defined by structural inflows from sovereign and corporate treasuries, declining volatility and increased market stability
One key driver of this transformation is that over 30% of Bitcoin's circulating supply is now held by 216 centralized entities, including exchanges, ETFs/Funds, public and private companies, governments, and DeFi contracts.
Another factor is the concentration among top players: 65%–90% of Bitcoin in most institutional categories is controlled by the top 3 entities, with private companies being the only slightly more distributed segment. However, the early adopters still dominate and define institutional structure.
Gemini highlights that since 2018, Bitcoin's price swings have steadily calmed, making it more predictable and attractive to long-term capital. The 30.9% supply held by institutional treasuries adds structural support, helping suppress wild price movements.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46027460/bitcoin-veteran-trader-goes-long-again-after-15-million-in-losses-will-third-time-be-the-charm">Bitcoin Veteran Trader Goes Long Again After $15 Million In Losses — Will Third Time Be The Charm?</a>
Why It Matters: Gemini also points to Bitcoin's reflexivity, meaning small capital inflows can drive disproportionate price increases. On average, $1 of investment adds $1.70 to Bitcoin's market capitalization, in bull markets, the impact rises to $3.70 and in short bursts, it can spike up to $25 per $1 invested.
This dynamic makes sovereign and institutional participation even more powerful, with potential to fuel self-reinforcing rallies.
In essence, Bitcoin is no longer just a speculative asset. It's becoming a strategic macroeconomic instrument, shaped by centralized institutions, sovereign wealth strategies, and long-term financial infrastructure.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46023419/bitcoin-ethereum-xrp-dogecoin-hold-steady-no-top-in-sight-plenty-of-room-to-grow">Bitcoin, Ethereum, XRP, Dogecoin Hold Steady: No Top In Sight, &#8216;Plenty Of Room To Grow&#8217;</a></li>
</ul>
Photo: Shutterstock

Bitcoin Quietly Entered A New Era In March: Here's What's Really Behind It

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) on Friday <a href="https://dmdwarrior.com/capricor-therapeutics-announces-positive-4-year-data-of-deramiocel-cap-1002-in-duchenne-muscular-dystrophy/?_gl=1&#x2A;9g80lr&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEz&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTA0NDUyNDkkbzQ1MiRnMSR0MTc1MDQ0NjQxOSRqMTUkbDAkaDExNjcwNDQzNDI.">released</a> four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company&#8217;s lead cell therapy candidate for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne Muscular Dystrophy (DMD)</a>.
After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline.
Further, a subgroup analysis of patients with baseline Left Ventricular Ejection Fraction (LVEF) >45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44115317/capricor-therapeutics-cell-therapy-goes-under-priority-fda-review-for-duchenne-associated-heart-condition" rel="noreferrer noopener">Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition</a>
Additionally, treatment continued to slow skeletal muscle disease progression, as measured by performance of the upper limb (PUL v2.0), with patients experiencing a smaller average decline in the fourth year (0.6 points) compared to the <a href="https://www.benzinga.com/pressreleases/25/06/g46025161/capricor-therapeutics-announces-positive-4-year-data-from-hope-2-open-label-extension-study-of-der" target="_blank" rel="noreferrer noopener">first year (1.8 points)</a>.
Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study.
&#8220;These four-year data reinforce the strength and durability of Deramiocel&#8217;s clinical benefit and favorable safety profile across both cardiac and skeletal muscle function,&#8221; said Linda Marbán, CEO of Capricor Therapeutics. &#8220;With our BLA under priority review and several key regulatory steps now completed, we are executing with focus and urgency as we move toward potential approval.
CAPR Price Action: CAPR stock is down 31.75% at $8.16 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" target="_blank" rel="noreferrer noopener">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a></li>
</ul>

CAPR

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Editor&#8217;s note: This article was updated to correct the details of the ETF.
<a href="https://www.benzinga.com/etfs">AI-themed ETFs</a> have proliferated in recent years, and many of them loaded with so-called &#8220;<a href="https://www.benzinga.com/topic/magnificent-seven">magnificent seven&#8221; tech giants</a>. 
However, not all are designed to endure the next innovation cycle. As the discussion moves from &#8220;what&#8217;s hot&#8221; to &#8220;what stands the test of time,&#8221; a new generation of ETFs is on the rise—those that adapt.
One such fund is the Dan IVES Wedbush AI Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVES#NYSE">IVES</a>). The <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45774136/wedbush-launches-ai-revolution-etf-backed-by-dan-ives-proprietary-tech-picks">ETF, launched on June 4</a>, managed to <a href="https://www.globenewswire.com/news-release/2025/06/13/3099005/0/en/Dan-IVES-AI-Revolution-ETF-Surpasses-100-Million-AUM-Within-First-Trading-Week-of-Wedbush-Fund-Advisers-Inaugural-Offering.html">pull</a> in $100 million in only five trading days.
IVES &#8220;is built to be disciplined and transparent,&#8221; Wedbush Fund Advisers CIO Cullen Rogers tells Benzinga. &#8220;We don't react to short-term performance or headlines.&#8221;
IVES rebalances quarterly and aligns with revisions to the AI30 model developed by Wedbush&#8217;s Dan Ives, who created the methodology. This frequency steers clear of performance-chasing whiplash from more active managers, while retaining thematic relevance.
The fund &#8220;follows a clear set of rules and reflects the ongoing evolution of Dan's AI30 framework. That combination of research-driven insight alongside a passive index structure gives us the ability to stay focused on the long term,&#8221; Rogers added.
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45978750/why-smart-money-is-spreading-out-etf-flows-signal-surge-in-portfolio-diversification">Why Smart Money Is Spreading Out: ETF Flows Signal Surge In Portfolio Diversification</a>
<h2 class="wp-block-heading">The Case Against Static AI ETFs</h2>
Global X Robotics &amp; Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>) and ROBO Global Robotics and Automation ETF (ROBO) both have portfolios that lean towards robotics, semiconductors, and infrastructure-heavy hardware. 
BOTZ, for example, has Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and Keyence (OTCPK: KYCCF) as its leading holdings. 
ROBO has a strong tilt into industrials and health tech.
But these ETFs tend to be afflicted by static index approaches that fail to adjust rapidly to new AI subsectors like inference engines, generative software, or quantum compute.
<h2 class="wp-block-heading">Inside IVES: A Living Portfolio For A Moving Target</h2>
IVES employs a modified market-cap weighting strategy to keep its biggest bets in check. Yes, it includes the likes of Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia, and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). However, it also leaves room for lesser-known high-conviction picks.
&#8220;We intentionally moved away from traditional straight-line market-cap weighting to avoid exactly that issue (overconcentration and valuation risk tied to the magnificent seven stocks). The modified market-cap weighting approach we use helps large-cap leaders hold influence, but it also prevents them from overwhelming the rest of the portfolio. At the same time, it gives room for smaller, high-conviction names to matter,&#8221; said Rogers.
IVES takes a tight, research-driven approach, Rogers explains. 
"This isn't about market timing — it's about giving investors access to the companies actually building and monetizing the AI revolution, in a format that's disciplined and transparent," he adds.
<h2 class="wp-block-heading">What Happens In A Downturn?</h2>
With valuations across the tech sector under renewed scrutiny, some wonder if AI ETFs are a bubble waiting to pop. Rogers isn't fazed. "Short-term market swings are part of investing, but IVES is built for the long run. What sets the fund apart is its ability to evolve with the AI ecosystem. Not just where it is today, but where it&#8217;s going. That's the advantage of anchoring the portfolio to Dan's ongoing research. As AI matures and new players, platforms, or verticals emerge, the index can adapt," he said.
&#8220;If the center of gravity in AI shifts from semis to inference, or from traditional compute to quantum, Dan's research is positioned to catch that. And our structure is designed to follow it. So even through a downturn, we're confident the fund will stay aligned with the most important parts of the AI value chain as they evolve,&#8221; Rogers emphasized.
Contrast that with holdings such as BOTZ, where old-school industrials and automation stocks constitute a huge percentage of the assets. They&#8217;re exposed to AI, perhaps, but sometimes indirectly and without the agility to change direction quickly.
<h2 class="wp-block-heading">Investor Takeaway: Adaptive &gt; Aggressive</h2>
For individual investors, the message is straightforward: not to conflate AI exposure with AI relevance. BOTZ funds might have expansive baskets, but that expansiveness tends to be at the expense of thematic integrity and forward-looking design. ROBO still stands for its robotics theme and first-mover appeal, but perhaps it will not be the final say on AI innovation as it extends into software.
IVES, on the other hand, presents a more streamlined style that balances conviction with agility. It&#8217;s not attempting to be everywhere, it&#8217;s trying to be where the AI narrative is really headed.
If the previous cycle of AIs revolved around who could train the largest model, perhaps the next will be a question of who can best monetize it. In that game, flexibility, not merely exposure, may be the ultimate advantage.
As Rogers summarizes: &#8220;IVES isn't a static snapshot, it's a living framework.&#8221;
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45975763/risk-on-revival-growth-themed-etfs-hit-52-week-highs-as-market-calms-down">Risk-On Revival: Growth-Themed ETFs Hit 52-Week Highs As Market Calms Down</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

ETFs

AMZN

BOTZ

ISRG

IVES

KYCCF

MSFT

NVDA

Beyond Magnificent 7: Can Thematic ETFs Like IVES Lead The Next Wave Of AI Investing? CIO Cullen Rogers Explains (CORRECTED)

Coinbase Global shares are trading higher after the company announced it secured an EU crypto license.

Investors with a lot of money to spend have taken a bullish stance on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SBUX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Starbucks.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $190,344, and 4 are calls, for a total amount of $280,005.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $95.0 for Starbucks over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Starbucks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Starbucks's substantial trades, within a strike price spectrum from $85.0 to $95.0 over the preceding 30 days.
<h3>Starbucks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446098_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$1.15</td>
<td>$1.09</td>
<td>$1.15</td>
<td>$94.00</td>
<td>$126.5K</td>
<td>742</td>
<td>1.4K</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.55</td>
<td>$5.25</td>
<td>$5.5</td>
<td>$95.00</td>
<td>$82.5K</td>
<td>2.7K</td>
<td>150</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$8.05</td>
<td>$7.55</td>
<td>$7.7</td>
<td>$85.00</td>
<td>$77.0K</td>
<td>4.6K</td>
<td>100</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.25</td>
<td>$95.00</td>
<td>$54.3K</td>
<td>1.2K</td>
<td>172</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.25</td>
<td>$2.19</td>
<td>$2.19</td>
<td>$95.00</td>
<td>$42.5K</td>
<td>4.0K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries at the end of March 2025. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
<h3>Where Is Starbucks Standing Right Now?</h3>
<ul>
<li>With a volume of 4,443,349, the price of SBUX is up 1.11% at $93.31. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 39 days.</li>
</ul>
<h3>Expert Opinions on Starbucks</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $93.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from TD Securities downgraded its rating to Hold, setting a price target of $90. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Starbucks, which currently sits at a price target of $95. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Starbucks, which currently sits at a price target of $100. 
&#x2A; Reflecting concerns, an analyst from TD Securities lowers its rating to Hold with a new price target of $90. 
&#x2A; In a cautious move, an analyst from TD Securities downgraded its rating to Hold, setting a price target of $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Starbucks with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

SBUX

Starbucks Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson &amp; Johnson.
Looking at options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $1,337,900 and 2, calls, for a total amount of $123,232.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $145.0 to $160.0 for Johnson &amp; Johnson during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Johnson &amp; Johnson options trades today is 3709.43 with a total volume of 4,332.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Johnson &amp; Johnson's big money trades within a strike price range of $145.0 to $160.0 over the last 30 days.
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446093_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.5</td>
<td>$9.85</td>
<td>$10.25</td>
<td>$160.00</td>
<td>$809.7K</td>
<td>4.0K</td>
<td>790</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.25</td>
<td>$150.00</td>
<td>$256.7K</td>
<td>6.3K</td>
<td>822</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$145.00</td>
<td>$80.5K</td>
<td>2.1K</td>
<td>90</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.9</td>
<td>$10.5</td>
<td>$10.9</td>
<td>$160.00</td>
<td>$73.0K</td>
<td>4.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.7</td>
<td>$6.55</td>
<td>$6.55</td>
<td>$155.00</td>
<td>$65.5K</td>
<td>4.1K</td>
<td>130</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 4,769,606, with JNJ's price down by -0.69%, positioned at $149.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 26 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $181.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $181. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Johnson & Johnson Unusual Options Activity For June 20

Fintech

Commodities

Press Releases

Lion Group Holding Makes Strategic Investment of Agunua Technology, to Explore New Opportunities in Carbon Finance

Lion Announces Plan to Implement ADS Ratio Change

LGHL Relaunches Crypto Operations to Broaden Access to Digital Assets

LGHL Secures $600 Million Facility to Launch Hyperliquid (HYPE) Treasury

Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings

EYEN

KIDZ

LGHL

VVPR

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

AMTD IDEA

AtlasClear Holdings

Dominari Holdings

Garden Stage

Lazard

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Glb

mF International Limited - Class A Ordinary Shares

mF International

Marex Group

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

PJT Partners

Plutus Financial Group Limited - Ordinary Shares

Plutus Financial Group

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

B. Riley Financial

Siebert Finl

Solowin Holdings - Class A Ordinary Share

Solowin Holdings

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

UP Fintech Holding

TOP Financial Group Limited - Class A Ordinary Shares

TOP Finl Gr

Virtu Financial, Inc. Class A Common Stock

Virtu Finl

Top KingWin Ltd - Class A Ordinary Shares

Top KingWin

Waton Financial Limited - Ordinary Shares

Comments

Lion Group Holding

Lion Group Holding (LGHL) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL